Market Cap | 5.56B | P/E | 7.39 | EPS this Y | 5.30% | Ern Qtrly Grth | -19.40% |
Income | 1B | Forward P/E | 4.74 | EPS next Y | 3.40% | 50D Avg Chg | 6.00% |
Sales | 6.35B | PEG | 1.39 | EPS past 5Y | -15.59% | 200D Avg Chg | -10.00% |
Dividend | 5.00% | Price/Book | N/A | EPS next 5Y | 3.10% | 52W High Chg | -34.00% |
Recommedations | 2.80 | Quick Ratio | 0.86 | Shares Outstanding | 257.47M | 52W Low Chg | 16.00% |
Insider Own | 0.17% | ROA | 7.27% | Shares Float | 256.64M | Beta | 0.82 |
Inst Own | 79.86% | ROE | - | Shares Shorted/Prior | 7.76M/8.69M | Price | 21.81 |
Gross Margin | 58.59% | Profit Margin | 15.76% | Avg. Volume | 2,234,525 | Target Price | 23.14 |
Oper. Margin | 24.02% | Earnings Date | Oct 31 | Volume | 1,771,141 | Change | 0.37% |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
JP Morgan | Underweight | Sep 6, 24 |
Goldman Sachs | Neutral | May 6, 24 |
Goldman Sachs | Neutral | May 3, 24 |
Piper Sandler | Overweight | Apr 29, 24 |
Goldman Sachs | Neutral | Feb 20, 24 |
Piper Sandler | Overweight | Nov 22, 23 |
Goldman Sachs | Neutral | Nov 3, 23 |
Piper Sandler | Overweight | Oct 25, 23 |
Morgan Stanley | Equal-Weight | Oct 11, 23 |